
FDA Approves Pemigatinib for Relapsed or Refractory Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.





























